Biocryst Pharmaceuticals buy JPMorgan Chase & Co.
Start price
06.05.25
/
50%
€9.37
Target price
06.05.26
€11.51
Performance (%)
-20.14%
Price
18:49
€7.48
Summary
This prediction is currently active. The prediction for Biocryst Pharmaceuticals disappoints with a performance of -20.14%. This prediction currently runs until 06.05.26. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Biocryst Pharmaceuticals | 14.228% | 14.228% |
| iShares Core DAX® | -1,31 % | -0,78 % |
| iShares Nasdaq 100 | 1,98 % | -2,04 % |
| iShares Nikkei 225® | 0,59 % | 6,71 % |
| iShares S&P 500 | 1,42 % | -0,48 % |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Biocryst Pharmaceuticals diskutieren
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its price target raised by analysts at JPMorgan Chase & Co. from $10.00 to $13.00. They now have an "overweight" rating on the stock.
Ratings data for BCRX provided by MarketBeat
Stopped prediction by JPMorgan_Chase___Co_ for Biocryst Pharmaceuticals
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€4.86
20.11.23
20.11.23
€9.15
20.11.24
20.11.24
44.15%
21.11.24
21.11.24
